Regions
MAIN/REGIONS
regions/
Regions
  1. Americas
  2. Asia & Oceania
  3. Europe
  4. Middle East & Africa
  1. Solutions
  2. Products
  3. Insights
  4. About
  5. Careers
  6. Contact Us
MAIN/search
MAIN/Solutions
Solutions/
SOLUTIONS
  • Research & Development
  • Real World Evidence
  • Commercialization
  • Safety & Regulatory Compliance
  • Technologies
  • Patient Engagement
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
THERAPEUTIC AREAS

Impacting People's Lives

"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.

LEARN MORE
Harness the power to transform clinical development

Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.

Research & Development Overview
Research & Development Quick Links
Real World Evidence. Real Confidence. Real Results.

Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.

REAL WORLD EVIDENCE OVERVIEW
Real World Evidence Quick Links
See markets more clearly. Opportunities more often.

Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.

COMMERCIALIZATION OVERVIEW
Commercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.

Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.

COMPLIANCE OVERVIEW
Safety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.

When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.

TECHNOLOGIES OVERVIEW
Technology Quick Links
Advance your patient engagement strategy

Discover new patient engagement possibilities with IQVIA insights, expertise, and technology-driven solutions.

Patient Engagement Overview
Patient Engagement Quick Links
MAIN/Products
Products/
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
REAL WORLD PRODUCTS

CASE STUDY

"Data in a Day

LEARN MORE
MAIN/Insights
Insights/
BLOGS, WHITE PAPERS & CASE STUDIES

Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.

DISCOVER INSIGHTS
THE IQVIA INSTITUTE

An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.

SEE LATEST REPORTS

INSTITUTE REPORT

"Global Trends in R&D 2024

READ MORE

EMEA Insights

"IQVIA thought leadership with a focus on EMEA.

Learn more

WHITE PAPER

"DCTs Deliver Big ROI

LEARN MORE

WHITE PAPER

"Capturing value at scale: The $4 billion RWE imperative

LEARN MORE
MAIN/About
About/
FEATURED INNOVATIONS
  • IQVIA Connected Intelligence™
  • IQVIA Healthcare-grade AI™
  • Human Data Science Cloud
  • IQVIA Innovation Hub
  • Decentralized Trials
  • Patient Experience powered by Apple
WHO WE ARE
NEWS & RESOURCES

INVESTOR RELATIONS

"Visit our investor relations site for more information.

LEARN MORE
Unlock your potential to drive healthcare forward

By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.

LEARN MORE
IQVIA AI is Healthcare-grade AI

Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.

LEARN MORE
Your healthcare data deserves more than just a cloud.

The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.

LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships

The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.

LEARN MORE
Proven, faster DCT solutions

IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.

LEARN MORE
IQVIA Patient Experience Solutions powered by Apple

Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm. IQVIA and Apple are collaborating to bring this exciting future of personalized care directly to devices patients already have and use.

LEARN MORE
MAIN/Careers
Careers/
WORKING AT IQVIA

Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.

LEARN MORE
LIFE AT IQVIA

Careers, culture and everything in between. Find out what’s going on right here, right now.

LEARN MORE

WE’RE HIRING

"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.

SEARCH JOBS
MAIN/Contact Us
Contact Us/
Institute Report
Orphan Drugs in the United States
Rare disease innovation and cost trends through 2019
Dec 03, 2020
To download files, please accept Functional Cookies. These cookies provide enhanced functionality for a better user experience.

About the report

Significant and transformative innovations for patients with rare disease have become available in 2019, highlighting the commitment made by manufacturers and regulators to these patients. The significant increases in the numbers of orphan approvals has raised orphan share of invoice spending from 2% in 1992 to 11% in 2019. However, rare disease patients continue to face hurdles in receiving treatment despite the increase in approvals and use of orphan medicines. In addition, access to rare disease medicines have been confounded by the COVID-19 pandemic, as the challenges rare disease patients face in starting new treatments have been exacerbated by widespread health system disruptions. This report discusses the current innovation in rare disease treatments, trends in overall drug spending levels and growth, and the effect of COVID-19 on patients.

Report Summary

In 2019, there were significant advances in treatments for rare diseases, underscoring the commitment to patients by manufacturers and regulators. The report finds that orphan indications have now reached 838 in total since the passage of the Orphan Drug Act and have been granted to 564 distinct drugs, with transformative innovations including cutting-edge gene and nucleotide therapies. In addition to novel treatments, continued investment and commitment by manufacturers to pursue multiple orphan indications has led to increases in the number of patients eligible for treatment. For example, as of 2019, 90% of cystic fibrosis patients are eligible for targeted treatment, compared to only 4% in 2012. 

In addition to innovation, the report also examines overall levels of orphan medicine spending and cost and finds that invoice spending on orphan indications accounted for 11% of the United States’ $518 billion in invoice spending in 2019. Another significant finding is that approximately 39% of drugs with orphan indications cost more than $100,000 annually, but the average annual cost of an orphan treatment was well below, at $32,000. The ongoing COVID-19 pandemic has negatively affected new orphan prescription starts, which are cumulatively down 21% since the beginning of the pandemic. This means that to-date, almost 48,000 new therapy starts have not taken place, a substantial impact to rare disease patients.

Key Findings


The total number of orphan indications reached 838 from the passage of the Orphan Drug Act to the end of 2019 and were awarded to 564 distinct drugs.

Cumulative Number of Orphan Indications and Distinct Drugs with at Least One Orphan Indication by Year of Marketing Approval

  • In the last three years, there have been 246 new orphan indications, which is approximately 30% of the total indications ever granted under the Orphan Drug Act (ODA). 
  • The number of approved orphan indications is growing faster than the number of drugs, as some drugs have multiple indications. 
  • In 2019, 25% of drugs had more than one orphan indication, as multiple orphan indications for the same medicine are increasingly common, particularly in cancer and autoimmune diseases

A continued investment by manufacturers in cystic fibrosis has expanded the treatable patient population to 90% of estimated prevalence.

Timeline of Cystic Fibrosis Orphan Indications and Share of Eligible Treatment Population, 2012–2019
  • Continued investment by manufacturers in orphan indications has brought critical treatments to underserved patients in a relatively short amount of time, as seen in the cystic fibrosis patient population. 
  • In 2012, ivacaftor (Kalydeco) received its first orphan indication for patients with a G551D mutation in the CFTR gene, found in approximately 4% of patients.
  • Subsequent label expansions for ivacaftor as well as approvals and label expansions of ivacaftor/lumacaftor (Orkambi), ivacaftor/tezecaftor (Symdeko), and the 2019 approval of Trikafta have expanded the treatable patient population to 90% of prevalence. 

Orphan indication invoice spending accounted for 11% of United States’ invoice spending, and totaled $58 billion in 2019.

Invoice Spending on Orphan Drugs in the United States 1992–2019, US$Bn

  • The total invoice spending on orphan indications accounted for $58 billion of total invoice spending in 2019, while $378 billion was spent on non-orphan drugs. 
  • $82 billion of invoice spending was on the non-orphan indications of drugs that have both orphan and non-orphan indications.
  • The significant increase in the numbers of orphan approvals has raised orphan share of invoice spending from 2% in 1992 to 11% in 2019, and up from 7% of invoice spending in 2013.

Since the start of the COVID-19 pandemic, new therapy start prescriptions are cumulatively down 31%, while new patients initiating orphan drug therapy are down 21%.

Cumulative Change from Baseline in Total Market and Orphan Drug New Therapy Starts During COVID-19
 
  • During the ongoing COVID-19 pandemic, new therapy starts (where a patient has not been on a treatment in the same therapy class in the last year) have been significantly affected, suggesting new orphan disease diagnoses are not occurring. 
  • However, orphan drug new start prescriptions have been more insulated from health system disruptions than other segments, with a cumulative decrease of 21% in new start prescriptions from baseline.
  • As rare diseases typically go undiagnosed longer than more common diseases and require many physician visits to receive a confirmed diagnosis, COVID-19 could be delaying initial diagnosis for many patients with rare diseases.
Contact Us